{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:46Z","timestamp":1772166106742,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03039-2","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T08:23:38Z","timestamp":1766651018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct compositional alterations in plasma lipoproteins in type 2 diabetes: a cross-sectional study of healthy individuals and diabetics with and without cardiovascular comorbidities"],"prefix":"10.1186","volume":"25","author":[{"given":"Elena","family":"Tsay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diyora","family":"Kurmaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharofiddin","family":"Nuriddinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Tsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanobar","family":"Abduxalimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyibjon Sodiqjonovich","family":"Bozorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zamira","family":"Khalimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren Balling","family":"Engelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faidon","family":"Magkos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilbar","family":"Dalimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6580-2034","authenticated-orcid":false,"given":"Bekzod","family":"Khakimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"issue":"5","key":"3039_CR1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s00125-021-05415-5","volume":"64","author":"TM Batista","year":"2021","unstructured":"Batista TM, Haider N, Kahn CR. Defining the underlying defect in insulin action in type 2 diabetes. Diabetologia. 2021;64(5):994\u20131006.","journal-title":"Diabetologia"},{"issue":"1","key":"3039_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"C-X Ma","year":"2022","unstructured":"Ma C-X, Ma X-N, Guan C-H, Li Y-D, Mauricio D, Fu S-B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"3039_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","volume":"9","author":"J Pearson-Stuttard","year":"2021","unstructured":"Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3039_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.2337\/dc15-2308","volume":"39","author":"JL Harding","year":"2016","unstructured":"Harding JL, Shaw JE, Peeters A, Davidson S, Magliano DJ. Age-specific trends from 2000\u20132011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. Diabetes Care. 2016;39(6):1018\u201326.","journal-title":"Diabetes Care"},{"issue":"4","key":"3039_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2337\/dc08-9018","volume":"31","author":"JD Brunzell","year":"2008","unstructured":"Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation. Diabetes Care. 2008;31(4):811\u201322.","journal-title":"Diabetes Care"},{"key":"3039_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117545","volume":"394","author":"L Luciani","year":"2024","unstructured":"Luciani L, Pedrelli M, Parini P. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes. Atherosclerosis. 2024;394:117545.","journal-title":"Atherosclerosis"},{"issue":"4","key":"3039_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40265-013-0023-5","volume":"73","author":"JM Chehade","year":"2013","unstructured":"Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73(4):327\u201339.","journal-title":"Drugs"},{"issue":"6","key":"3039_CR8","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.3892\/mmr.2017.7831","volume":"16","author":"P Zhang","year":"2017","unstructured":"Zhang P, Gao J, Pu C, Zhang Y. Apolipoprotein status in type 2 diabetes mellitus and its complications (Review). Mol Med Rep. 2017;16(6):9279\u201386.","journal-title":"Mol Med Rep"},{"issue":"1","key":"3039_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s41745-022-00346-5","volume":"103","author":"A Gupta","year":"2023","unstructured":"Gupta A, Gupta R. Current understanding of diabetic dyslipidemia: a review. J Indian Inst Sci. 2023;103(1):287\u2013307.","journal-title":"J Indian Inst Sci"},{"issue":"1","key":"3039_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/qjmed\/hci154","volume":"99","author":"M Rizzo","year":"2006","unstructured":"Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM: An Int J Med. 2006;99(1):1\u201314.","journal-title":"QJM: An Int J Med"},{"issue":"1","key":"3039_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12933-021-01348-w","volume":"20","author":"S Sokooti","year":"2021","unstructured":"Sokooti S, Flores-Guerrero JL, Heerspink HJL, Connelly MA, Bakker SJL, Dullaart RPF. Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study. Cardiovasc Diabetol. 2021;20(1):156.","journal-title":"Cardiovasc Diabetol"},{"key":"3039_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00039","author":"A Jomard","year":"2020","unstructured":"Jomard A, Osto E. High density lipoproteins: metabolism, function, and therapeutic potential. Front Cardiovasc Med. 2020. https:\/\/doi.org\/10.3389\/fcvm.2020.00039.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"3039_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218533","volume":"14","author":"\u00c1 Hern\u00e1ez","year":"2019","unstructured":"Hern\u00e1ez \u00c1, Soria-Florido MT, Schr\u00f6der H, Ros E, Pint\u00f3 X, Estruch R, et al. Role of HDL function and LDL atherogenicity on cardiovascular risk: a comprehensive examination. PLoS ONE. 2019;14(6):e0218533.","journal-title":"PLoS ONE"},{"issue":"7","key":"3039_CR14","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/ijms23073967","volume":"23","author":"K-H Cho","year":"2022","unstructured":"Cho K-H. The current status of research on high-density lipoproteins (HDL): a paradigm shift from HDL quantity to HDL quality and HDL functionality. Int J Mol Sci. 2022;23(7):3967.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3039_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","volume":"37","author":"JR Sowers","year":"2001","unstructured":"Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension. 2001;37(4):1053\u20139.","journal-title":"Hypertension"},{"issue":"2","key":"3039_CR16","first-page":"113","volume":"87","author":"OO Oyelola","year":"1995","unstructured":"Oyelola OO, Ajayi AA, Babalola RO, Stein EA. Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients. J Natl Med Assoc. 1995;87(2):113\u20138.","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"3039_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.51152\/jbarbiomed.v5i1.25","volume":"5","author":"J Jha","year":"2022","unstructured":"Jha J, Malhotra V, Jha O, Gupta S. Study of lipid profile in diabetes mellitus with and without hypertension. J Basic Appl Res Biomed. 2022;5(1):31\u20136.","journal-title":"J Basic Appl Res Biomed"},{"issue":"2","key":"3039_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.rpedm.2016.06.003","volume":"11","author":"AM Monteiro","year":"2016","unstructured":"Monteiro AM, Palma I. Lipid profile and persistent lipid abnormalities in diabetic patients\u2013a retrospective study. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo. 2016;11(2):197\u2013201.","journal-title":"Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo"},{"issue":"11","key":"3039_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","volume":"28","author":"LA Leiter","year":"2011","unstructured":"Leiter LA, Lundman P, da Silva PM, Drexel H, J\u00fcnger C, Gitt AK. Investigators obotD: persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the dyslipidaemia international study. Diabet Med. 2011;28(11):1343\u201351.","journal-title":"Diabet Med"},{"key":"3039_CR20","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S0140-6736(97)90024-6","volume":"350","author":"M Syv\u00e4nne","year":"1997","unstructured":"Syv\u00e4nne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350:S20\u20133.","journal-title":"Lancet"},{"issue":"2","key":"3039_CR21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/acs.analchem.1c01654","volume":"94","author":"B Khakimov","year":"2022","unstructured":"Khakimov B, Hoefsloot HCJ, Mobaraki N, Aru V, Kristensen M, Lind MV, et al. Human blood lipoprotein predictions from H-1 NMR spectra: protocol, model performances, and cage of covariance. Anal Chem. 2022;94(2):628\u201336.","journal-title":"Anal Chem"},{"issue":"15","key":"3039_CR22","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1021\/acs.analchem.7b01329","volume":"89","author":"SM Centelles","year":"2017","unstructured":"Centelles SM, Hoefsloot HCJ, Khakimov B, Ebrahimi P, Lind MV, Kristensen M, et al. Toward reliable lipoprotein particle predictions from NMR spectra of human blood: an interlaboratory ring test. Anal Chem. 2017;89(15):8004\u201312.","journal-title":"Anal Chem"},{"key":"3039_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.aca.2020.02.025","volume":"1108","author":"B Khakimov","year":"2020","unstructured":"Khakimov B, Mobaraki N, Trimigno A, Aru V, Engelsen SB. Signature mapping (SigMa): an efficient approach for processing complex human urine H-1 NMR metabolomics data. Anal Chim Acta. 2020;1108:142\u201351.","journal-title":"Anal Chim Acta"},{"key":"3039_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cem.1180010306","author":"L St\u00e5hle","year":"1987","unstructured":"St\u00e5hle L, Wold S. Partial least squares analysis with cross\u2010validation for the two\u2010class problem: a monte carlo study. J Chemom. 1987. https:\/\/doi.org\/10.1002\/cem.1180010306.","journal-title":"J Chemom"},{"issue":"6","key":"3039_CR25","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1021\/acs.jproteome.6b00109","volume":"15","author":"B Khakimov","year":"2016","unstructured":"Khakimov B, Poulsen SK, Savorani F, Acar E, Gurdeniz G, Larsen TM, et al. New nordic diet versus average Danish diet: a randomized controlled trial revealed healthy long-term effects of the New Nordic diet by GC-MS blood plasma metabolomics. J Proteome Res. 2016;15(6):1939\u201354.","journal-title":"J Proteome Res"},{"issue":"9","key":"3039_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5551\/jat.RV17023","volume":"25","author":"T Hirano","year":"2018","unstructured":"Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25(9):771\u201382.","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"3039_CR27","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","volume":"27","author":"RM Krauss","year":"2004","unstructured":"Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496\u2013504.","journal-title":"Diabetes Care"},{"key":"3039_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2017.05.031","volume":"263","author":"SW Shiu","year":"2017","unstructured":"Shiu SW, Wong Y, Tan KC. Pre-\u03b21 HDL in type 2 diabetes mellitus. Atherosclerosis. 2017;263:24\u20138.","journal-title":"Atherosclerosis"},{"issue":"4","key":"3039_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dbi19-0007","volume":"69","author":"A Chait","year":"2020","unstructured":"Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes. 2020;69(4):508\u201316.","journal-title":"Diabetes"},{"issue":"1","key":"3039_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/eci.12377","volume":"45","author":"RP Dullaart","year":"2015","unstructured":"Dullaart RP, de Vries R, Kwakernaak AJ, Perton F, Dallinga-Thie GM. Increased large VLDL particles confer elevated cholesteryl ester transfer in diabetes. Eur J Clin Invest. 2015;45(1):36\u201344.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"3039_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886\u201399.","journal-title":"Diabetologia"},{"issue":"8","key":"3039_CR32","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1172\/JCI5286","volume":"103","author":"B Lamarche","year":"1999","unstructured":"Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999;103(8):1191\u20139.","journal-title":"J Clin Invest"},{"issue":"4","key":"3039_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","volume":"49","author":"M Adiels","year":"2006","unstructured":"Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49(4):755\u201365.","journal-title":"Diabetologia"},{"issue":"2","key":"3039_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1559-4572.2008.00044.x","volume":"4","author":"HN Ginsberg","year":"2009","unstructured":"Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4(2):113\u20139.","journal-title":"J Cardiometab Syndr"},{"issue":"7","key":"3039_CR35","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","volume":"28","author":"M Adiels","year":"2008","unstructured":"Adiels M, Olofsson S-O, Taskinen M-R, Bor\u00e9n J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(7):1225\u201336.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3039_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159577","author":"AV Sorokin","year":"2022","unstructured":"Sorokin AV, Patel N, Abdelrahman KM, Ling C, Reimund M, Graziano G, et al. Complex association of apolipoprotein E-containing HDL with coronary artery disease burden in cardiovascular disease. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.159577.","journal-title":"JCI Insight"},{"issue":"13","key":"3039_CR37","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1161\/CIRCULATIONAHA.117.031276","volume":"137","author":"MK Jensen","year":"2018","unstructured":"Jensen MK, Aroner SA, Mukamal KJ, Furtado JD, Post WS, Tsai MY, et al. High-density lipoprotein subspecies defined by presence of apolipoprotein C-III and incident coronary heart disease in four cohorts. Circulation. 2018;137(13):1364\u201373.","journal-title":"Circulation"},{"issue":"9","key":"3039_CR38","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.2337\/db09-0206","volume":"58","author":"A Hiukka","year":"2009","unstructured":"Hiukka A, St\u00e5hlman M, Pettersson C, Levin M, Adiels M, Teneberg S, et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes. 2009;58(9):2018\u201326.","journal-title":"Diabetes"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03039-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:22:54Z","timestamp":1769599374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03039-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3039"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03039-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7318923\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and approved by the Ethical Committee of the Ministry of Public Health of the Republic of Uzbekistan (Approval No. 6\/11\u20131694). Written informed consent was obtained from all participants prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript is not under consideration elsewhere and will not be submitted to another journal until a final decision regarding its acceptability has been made.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}